Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.

Jie HeNatallia KalinavaParul DoshiDean C PavlickLee A AlbackerEricka M EbotHanna TukachinskyJames PrattGina FusaroGeoffrey R OxnardGeorge GreenDavid FabrizioJonathan Baden

Published in: Journal for immunotherapy of cancer (2023)

We observed that tTMB and bTMB had a statistically significant correlation, particularly for samples with high MSAF, and that this correlation applied across disease ontologies. Further investigation into the clinical utility of bTMB is warranted.

Keyphrases

small cell lung cancer
copy number
risk factors
gene expression